Marc Hellerstein News Today : Breaking News, Live Updates & Top Stories | Vimarsana

It's thought that T cells may provide longer-lasting protection against coronavirus than their protective counterparts—antibodies.

Print Current data show the first generation of COVID-19 vaccines are highly effective at preventing coronavirus infection and offer various degrees of protection against most variants, but for how long? In this episode, we discuss whether these current vaccines can provide lifetime immunity as emerging variants surface around the globe. Our guests are Dr. Otto O. Yang, associate chief in the Division of Infectious Diseases at David Geffen School of Medicine at UCLA, and Dr. Marc Hellerstein, a professor in the Department of Nutritional Sciences and Toxicology at UC Berkeley and at the De...

In a departure from traditional vaccine design, the leading Covid-19 shots trigger an immune response by leveraging the body’s own cellular mechanics to produce viral proteins. A nurse prepares a shot of the Pfizer-BioNTech Covid-19 vaccine at Guy’s Hospital in London two weeks ago. (AP Photo/Frank Augstein, file) (CN) — Pharmaceutical companies are holding out hope that the mRNA technology used to develop breakthrough Covid-19 vaccines is flexible enough to provide for seasonal shots in case immunity gained from initial vaccination is short-lived.   The first Covid-19 vaccine approve...